Amphastar Pharmaceuticals (NASDAQ:AMPH) Given New $30.00 Price Target at Needham & Company LLC

Amphastar Pharmaceuticals (NASDAQ:AMPH) had its price objective lowered by Needham & Company LLC from $34.00 to $30.00 in a research report sent to investors on Friday,Benzinga reports. Needham & Company LLC currently has a buy rating on the stock.

Several other analysts have also recently weighed in on the stock. Zacks Research cut shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 14th. Barclays began coverage on Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They set an “equal weight” rating and a $30.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research note on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $29.50.

Amphastar Pharmaceuticals Stock Performance

AMPH traded down $6.26 during trading on Friday, reaching $20.23. 1,965,411 shares of the company’s stock were exchanged, compared to its average volume of 368,258. The company has a quick ratio of 2.21, a current ratio of 3.12 and a debt-to-equity ratio of 0.78. The business has a 50 day moving average price of $27.23 and a 200 day moving average price of $27.01. Amphastar Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $31.26. The company has a market capitalization of $929.57 million, a P/E ratio of 9.97, a PEG ratio of 4.83 and a beta of 0.88.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Thursday, February 26th. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.24). Amphastar Pharmaceuticals had a return on equity of 17.74% and a net margin of 13.63%.The business had revenue of $183.11 million during the quarter, compared to analyst estimates of $190.48 million. As a group, analysts predict that Amphastar Pharmaceuticals will post 3.49 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total value of $256,419.40. Following the sale, the executive vice president directly owned 138,043 shares in the company, valued at approximately $3,616,726.60. The trade was a 6.62% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Floyd F. Petersen sold 2,426 shares of the stock in a transaction dated Friday, December 12th. The stock was sold at an average price of $25.92, for a total transaction of $62,881.92. Following the transaction, the director owned 71,368 shares of the company’s stock, valued at approximately $1,849,858.56. This represents a 3.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 13,950 shares of company stock valued at $363,925. 27.50% of the stock is owned by insiders.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Farther Finance Advisors LLC raised its stake in Amphastar Pharmaceuticals by 356.0% during the third quarter. Farther Finance Advisors LLC now owns 944 shares of the company’s stock worth $25,000 after acquiring an additional 737 shares in the last quarter. FNY Investment Advisers LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $26,000. Global Retirement Partners LLC increased its position in Amphastar Pharmaceuticals by 219.0% during the 3rd quarter. Global Retirement Partners LLC now owns 1,024 shares of the company’s stock worth $27,000 after purchasing an additional 703 shares in the last quarter. Quarry LP bought a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth $32,000. Finally, Hantz Financial Services Inc. grew its stake in shares of Amphastar Pharmaceuticals by 3,430.8% during the second quarter. Hantz Financial Services Inc. now owns 1,377 shares of the company’s stock worth $32,000 after buying an additional 1,338 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals News Roundup

Here are the key news stories impacting Amphastar Pharmaceuticals this week:

• Positive Sentiment: Management expects mid- to high-single-digit revenue growth for 2026 and is launching a new respiratory product, which provides a clear growth runway beyond the quarter that disappointed investors. Amphastar outlines mid- to high-single-digit revenue growth for 2026 while launching new respiratory product
• Positive Sentiment: Two sell-side shops lowered price targets from $34 to $30 but retained constructive ratings (Wells Fargo: overweight; Needham: buy), signaling that analysts still see significant upside from current levels despite trimming near-term assumptions. Analyst price target coverage
• Neutral Sentiment: Company published its Q4 press release, slide deck and conference call materials for investors to review detailed results and management commentary. These materials may clarify margin drivers and product cadence. Press release / slide deck
• Neutral Sentiment: Analyst and media write-ups (Zacks, Seeking Alpha, Investing.com) provide deeper metric-level analysis comparing results to estimates — useful for modeling but not new catalyst by itself. Zacks comparison of key metrics
• Negative Sentiment: Q4 results missed consensus: adjusted EPS of $0.73 vs. ~$0.97 expected and revenue of $183.1M vs. ~$190.5M, prompting investor concern about near-term growth and profit leverage. MarketBeat earnings summary
• Negative Sentiment: Market reaction has been amplified by heavy trading and coverage noting the miss; short-interest reports in public feeds are noisy/unclear but the immediate selloff reflects disappointment with the quarter. Yahoo finance: earnings miss and market reaction

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.